Search HDBuzz

Updates from uniQure about their gene therapy for Huntington's disease

Updates from uniQure about their gene therapy for Huntington's disease

uniQure is conducting safety trials of the first gene therapy for HD. A recent press release provided a 1 year update on the first group of 10 people who underwent surgery to receive this experimental drug. Let’s talk more about what it means.

Dr Leora Fox and Dr Rachel HardingJuly 11, 2022

uniQure gets the green light to resume testing HD gene therapy

uniQure gets the green light to resume testing HD gene therapy

Following a 3-month pause in enrollment due to concerns about side effects, uniQure shared the good news that their trial of the HD gene therapy AMT-130 will continue as planned, with new safety measures in place.

Dr Leora FoxNovember 03, 2022

Roche Phase II GENERATION HD2 study underway

Roche Phase II GENERATION HD2 study underway

Roche released a community letter in early 2023, to share that their Phase II clinical trial to study the huntingtin-lowering drug, tominersen, is now underway. In this article, we summarise the latest news about this huntingtin-lowering drug.

Dr Rachel HardingFebruary 14, 2023

Tipping the balance; new insights into HD genetic modifiers

Tipping the balance; new insights into HD genetic modifiers

A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.

Dr Rachel HardingSeptember 01, 2023

Putting it in print: GENERATION HD1 study results published

Putting it in print: GENERATION HD1 study results published

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and what’s next?

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezDecember 07, 2023

The director’s cut: how CAG repeats change the editing of genetic messages

The director’s cut: how CAG repeats change the editing of genetic messages

Scientists in Massachusetts have recently advanced our understanding of how repetitive sequences in DNA can disrupt the creation and editing of genetic messenger molecules in cells, and how this could lead to the production of harmful proteins.

Lucy CouplandMarch 26, 2024

Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial

Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial

More good news for the HD community from uniQure, whose one-and-done gene therapy appears safe and shows hints of slowing down signs and symptoms of the disease

Dr Rachel HardingAugust 16, 2024

Steadying genetic stumble could help slow Huntington's disease

Steadying genetic stumble could help slow Huntington's disease

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease

Dr Nicholas CaronFebruary 11, 2025

Successful gene therapy trial in Parkinson’s Disease gives hope for HD

Successful gene therapy trial in Parkinson’s Disease gives hope for HD

Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD

Dr Jeff CarrollMarch 31, 2011

A back-to-front hidden message in the HD gene?

A back-to-front hidden message in the HD gene?

Unzip your genes! A backwards message, hidden in the 'backup DNA' of the Huntington's disease gene... what does it me

Professor Ed WildAugust 19, 2011

You can also read About HDBuzz for information on HDBuzz or try your search on a search engine.

Donate

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.

With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you're able. More information...